Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment.Cancer Epidemiology, Biomarkers and Prevention.  27:1133-1141. 2018
2017 T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).Blood Advances.  1:2724-2728. 2017
2017 Publication outcomes of abstracts from the American Society of Hematology Annual Meeting.American Journal of Hematology.  92:E81-E83. 2017
2017 Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma.Leukemia.  31:1450-1453. 2017
2017 Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome.Cancer Epidemiology, Biomarkers and Prevention.  26:312-320. 2017
2016 Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers.Journal of the National Comprehensive Cancer Network.  14:837-847. 2016
2015 Impact of Tailored Education on Awareness of Personal Risk for Therapy-Related Complications Among Childhood Cancer Survivors.Journal of Clinical Oncology.  33:3887-3893. 2015
2015 Impact of care at comprehensive cancer centers on outcome: Results from a population-based study.Cancer.  121:3885-3893. 2015
2015 Long-term pulmonary function in survivors of childhood cancer.Journal of Clinical Oncology.  33:1592-1600. 2015
2015 Piecing together the puzzle of disparities in adolescents and young adults.Cancer.  121:1168-1171. 2015
2014 Impact of care at NCI Comprehensive Cancer Centers (NCICCC) on cancer outcome: Results from a population-based study.Journal of Clinical Oncology.  32:188. 2014
2014 Impact of treatment site in adolescents and young adults with central nervous system tumors.JNCI: Journal of the National Cancer Institute.  106:dju166. 2014
2013 Pitfalls of using administrative data sets to describe clinical outcomes in sickle cell disease.Medical and Pediatric Oncology.  60:1936-1939. 2013
2013 Relapse after treatment of pediatric Hodgkin lymphoma: outcome and role of surveillance after end of therapy.Medical and Pediatric Oncology.  60:1458-1463. 2013
2013 Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.British Journal of Haematology.  162:376-382. 2013
2012 Sickle cell disease in California: sociodemographic predictors of emergency department utilization.Medical and Pediatric Oncology.  58:66-73. 2012
2011 Sickle-cell disease in California: a population-based description of emergency department utilization.Medical and Pediatric Oncology.  56:413-419. 2011
2010 Health care reform 2010: expected favorable impact on childhood cancer patients and survivors.Cancer Journal.  16:554-562. 2010

Chapter

Year Title Altmetric
2017 Making Ends Meet: Financial Issues from the Perspectives of Patients and Their Health-Care Team.  667-685. 2017

Investigator On

  • AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2025
  • AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2024
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • Reduced Burden Of Oncology Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents, and Young Adults with CD20+ Mature B-Cell Lymphoma  awarded by NEW YORK MEDICAL COLLEGE 2017 - 2022
  • A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid┬«) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2021
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP 2015 - 2020
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2015 - 2020
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2020
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Developing a Network to Utilize Administrative and Clinical Data for Childhood, Adolescent and Young Adult Oncology Survivorship Research  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2018
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2018
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2018
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2017
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2017
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee 2015 - 2016
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2015
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015
  • Education And Training

  • Doctor of Medicine, University of Florida
  • Full Name

  • Julie Wolfson-Stockman
  • Blazerid

  • wolfsonj